HomeStock ScreenerAlivus Life SciencesQuarterly Results

Alivus Life Sciences Quarterly Results for Trading Insights

Latest Quarter Net Profit
₹565 Cr
QMarch 2026
Quarterly Results

In 2026, Alivus Life Sciences (ALIVUS) reported revenue ₹2,664 Cr and net profit ₹603 Cr. Analyse ALIVUS FII DII holdings to track promoter, FII and institutional holdings.

ALIVUS Quarterly Results — Revenue, Profit & EPS Highlights

Alivus Life Sciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View ALIVUS yearly price range for the annual high/low range and current price position.

  • Revenue of ₹2,612 Cr in March 2026 (+0.0% vs March 2026, +7.9% vs March 2025)
  • Net Profit of ₹565 Cr in March 2026 (+0.0% vs March 2026, +16.3% vs March 2025)
  • EBITDA of ₹858 Cr in March 2026 (+0.0% vs March 2026)
  • Operating Margin of 31.0% in March 2026 (+0.0pp vs March 2026)
  • Earnings Per Share of ₹45.99 in March 2026 (+0.0% vs March 2026)

Alivus Life Sciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS

ALIVUS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric 2026 March 2026 March 2025 March 2024 March 2023 QoQ YoY
Revenue (₹ Cr) 2,664 2,612 2,421 2,295 2,190 2.0% -
Net Profit (₹ Cr) 603 565 486 471 467 - -
EBITDA (₹ Cr) 885 858 717 686 671 - -
EPS (₹) 49.10 45.99 39.63 38.43 38.11 - -
Operating Margin (%) 31.0% 31.0% 29.0% 30.0% 30.0% - -

ALIVUS Share Price Trend — 1-Year Movement Across Quarterly Results

Alivus Life Sciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Alivus Life Sciences screener.

Profitability Ratios

Profit Margin 21.6%
EBITDA Margin 32.8%
Operating Margin 31.0%
ROE (Annual) 17.0%

Balance Sheet Highlights

Total Assets ₹3,983 Cr
Total Equity ₹3,332 Cr
Current Assets ₹2,649 Cr
Current Liabilities ₹143 Cr

Cash Flow Analysis

Operating Cash Flow ₹565 Cr
Investing Cash Flow ₹-570 Cr
Financing Cash Flow ₹-64 Cr
Net Cash Flow ₹-69 Cr

Current Market Data

Current Price ₹1430.80
Exchange NSE
Last Updated Sep 18, 2026

ALIVUS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Alivus Life Sciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Mar 2026
₹441,477.63 Cr 1837.3 15,018 2,710 -5.6% - 18.0% 162.6
Divis Laboratories
Mar 2026
₹247,469.81 Cr 9375.0 2,986 751 -5.0% - 25.2% 331.2
Torrent Pharmaceuti…
Mar 2026
₹188,719.51 Cr 4840.0 4,111 364 +27.7% +42.2% 8.9% 420.5
Cipla
Mar 2026
₹112,654.03 Cr 1394.5 6,612 543 -9.3% - 8.2% 203.0
Zydus Life Science
Mar 2026
₹112,607.65 Cr 1160.0 7,569 1,341 -4.3% - 17.7% 91.7
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores